| HR positive | HER2 positive | HR negative | HER2 negative | Her2-enriched | TN | All others |
---|---|---|---|---|---|---|---|
HR positive | – | – | 67% (POE; 9) | – | 79.4% (Fisher; 7) | 71.3% (Fisher; 8) | 67% (POE; 9) |
HER2 positive | – | – | – | 73.6% (Fisher; 9) | – | 59.5% (Fisher; 4) | 73.6% (Fisher; 9) |
HR negative | 67% (POE; 9) | – | – | – | – | – | 67% (POE; 9) |
HER2 negative | – | 73.6% (Fisher; 9) | – | – | – | – | 73.6% (Fisher; 9) |
HER2-enriched | 79.4% (Fisher; 7) | – | – | – | – | – | – |
TN | 71.3% (Fisher; 8) | 59.5% (Fisher; 4) | – | – | – | – | – |
All others | 67% (POE; 9) | 73.6% (Fisher; 9) | 67% (POE; 9) | 73.6% (Fisher; 9) | – | – | – |